

TITAN PHARMACEUTICALS INC  
Form 8-K  
June 21, 2011

# SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act 1934

Date of Report (Date of earliest event reported): June 17, 2011

## Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware

(State or other jurisdiction

of incorporation)

Edgar Filing: TITAN PHARMACEUTICALS INC - Form 8-K

<b>Delaware</b> (State or Other Jurisdiction)	<b>0-27436</b> (Commission	<b>94-3171940</b> (IRS Employer
<b>of Incorporation)</b>	<b>File Number)</b>	<b>Identification No.)</b>
<b>400 Oyster Point Blvd., Suite 505, South San Francisco, CA</b> (Address of Principal Executive Offices)	<b>Registrant's telephone number, including area code: 650-244-4990</b>	<b>94080</b> (Zip Code)
<b>(Former Name or Former Address, is Changed Since Last Report)</b>		

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01. Other Events.**

On June 17, 2011, Titan Pharmaceuticals, Inc. issued press releases providing information about its ongoing dialogue with the U.S. Food and Drug Administration regarding the Statistical Analysis Plan for its confirmatory Phase 3 study of Probuphine. The press releases are attached to this Current Report on Form 8-K as Exhibits 99.1 and 99.2.

**Item 9.01. Financial Statements and Exhibits**

(d) Exhibits

99.1 Press Release dated June 17, 2011

99.2 Press Release dated June 17, 2011

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TITAN PHARMACEUTICALS, INC.

By: /s/ Sunil Bhonsle  
Name: Sunil Bhonsle  
Title: President

Dated: June 21, 2011

Exhibit Index

Exhibit No.	Description
99.1	Press Releases dated June 17, 2011
99.2	Press Release dated June 17, 2011